Prescribing information

 

These are references resulting from the pivotal studies for Xolair® (omalizumab) in the treatment of chronic spontaneous urticaria (CSU).

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

The links below will take you to non-Novartis websites.

 

Kaplan A et al.
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

J Allergy Clin Immunol 2013;132:101−109.

View


Maurer M et al.
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

N Engl J Med 2013;368:924−935.

View


Saini SS et al.
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.

J Invest Dermatol 2015;135:67–75.

View

 

*A post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.1

CSU, chronic spontaneous urticaria; DLQI, Dermatology Life Quality Index; IgE, immunoglobulin E.

Reference

  1. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.
XSU20-C023 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]